[203Pb]Pb-PSMA-CA012 presented with optimal uptake, and a first-in-human dosimetry study was subsequently performed using [203Pb]Pb-PSMA-CA012 in two prostate cancer patients. This evidence concerns the gene FOLH1 and prostate carcinoma.